摘要
目的探讨冠心病（CHD）患者血清肺炎衣原体（CP-IgA）、高敏C反应蛋白（hsCRP）和IL-6水平与经皮冠状动脉介入治疗（PCI）术中、术后预后的关系。方法105例患者接受PCI治疗，术后观察7～10d，记录术中及围手术期内有无心血管事件发生。经PCI术的患者术后服用他汀类药物（3～6个月）及阿司匹林治疗，随访6个月，记录6个月内有无心血管事件发生。ELISA法测定入选对象手术当天的血清CP-IgA、hsCRP及IL-6的水平，比较它们与PCI围手术期、术后6个月内心血管事件发生之间的关系。结果围手术期高危组患者血清hsCRP及IL-6水平明显高于低危组患者（均P〈0．01）。术后6个月预后良好组患者血清CP-IgA水平明显低于预后不良组患者（P〈0．01）。结论术前血清hsCRP、IL-6水平可能与围手术期的预后相关；而术前血清CP-IgA水平可能与术后6个月的预后相关。
Objective To evaluate the relationship between the severity of coronary lesions, the prognosis of PCI, and chlamydia pneumonial （CP-IgA）, high sensitive C-reactive protein （hsCRP） and IL-6. Methods One hundred and five patients with established coronary heart disease, unstable angina accepted coronary angiography test and PCI operation. They were discharged with statins and aspirin treatment for 3-6 months and were observed for 6 months after PCI. Weather there were adverse events or not during and after PCI was registered. Serum values of CP-IgA, hsCRP and IL-6 were measured using ELISA. The relationship between adverse events during PCI and the outcome after PCI, and serum CP-IgA, hsCRP and IL-6 was assessed. Results In 105 patients with established coronary heart disease and unstable angina accepting PCI therapy, there were 23 patients with adverse events within 1 week after PCI （group 1） and 82 patients without adverse events within 1 week after PCI （group 2）. The hsCRP levels in group 1 was 42.87 ± 28.65 mg/L, the hsCRP levels in group 2 was 26.03± 18.15 mg/L （P〈0.01）. The IL-6 levels in group 1 was 3.48 ± 3.24 ng/L, the IL-6 levels in group 2 was 1.79± 1.88 ng/L （P〈0.05）. There was 2 patients who died, 9 patients accepting revascularization therapy again within 6 months after PCI （group 3）. There was no adverse events in other 81 patients （group 4）. The other 11 patients were out of connection. The CP-IgA levels in group 3 was 1.82 ± 0.68 COI, the CP-IgA levels in group 4 was 0.98 ± 0.72 COI（P〈 0.01）. Conclusion Levels of serum hsCRP and IL-6 are predictors of the early outcome in patients undergoing PCI. Levels of serum CP-IgA is a predictor of later outcome in patients undergoing PCI.
出处
《苏州大学学报（医学版）》
CAS
北大核心
2006年第4期637-639,共3页
Suzhou University Journal of Medical Science
关键词
冠心病
肺炎衣原体
高敏C反应蛋白
白细胞介素-6
经皮冠状动脉介入治疗
预后
coronary artery disease
chlamydia pneumoniae
high sensitive C-reactive protein
IL-6
percutaneous coronary intervention
prognosis
